TITLE

VICAL/TEVA SIGN SALES/MARKETING PACT FOR ALLOVECTIN

PUB. DATE
September 2009
SOURCE
Worldwide Biotech;Sep2009, Vol. 21 Issue 9, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the exclusive agreement reached by Vical Inc. with Abic Marketing Ltd. for sales and marketing of Vical's Allovectin-7(r) in Israel in 2009. Information on the drug as well as its mechanism of action is offered. Vical is said to be conducting an Allovectin-7(r) Immunotherapeutic for Metastatic Melanoma (AIMM) trial at more than 60 clinical sites. Also given is a brief company background on Vical.
ACCESSION #
43826759

 

Related Articles

  • BioAlliance Pharma and Teva Announce First License Agreement for Sitavig(r) for Israel.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that BioAlliance Pharma SA has signed a license agreement Abic Marketing Ltd. for the commercialization rights of the drug Sitavig in Israel. Sitavig was developed by BioAlliance Pharma for the treatment of recurrent labial herpes in immunocompetent patients presenting more...

  • Vical to stop development of Allovectin.  // Hem/Onc Today;9/25/2013, Vol. 14 Issue 18, p47 

    The article highlights the decision of Vical Inc. to abandon the development of velimogene aliplasmid (Allovectin), an investigational drug for treatment of patients with metastatic melanoma, after the trial failed to meet either the primary or secondary efficacy endpoints.

  • FDA, Vical Licensee Agree on Phase III Design for Collategene. Hollingsworth, Catherine // BioWorld Today;1/13/2010, Vol. 21 Issue 8, p4 

    The article reports on an agreement reached by AnGes MG Inc. with the U.S. Food and Drug Administration (FDA) concerning the design of a Phase III trial of Collategene. It is noted that Collategene has the potential to treat patients with peripheral arterial disease (PAD). The underlying...

  • Melanoma Drug Approvals Boost Biotechs' Confidence. Orelli, Brian // BioWorld Insight;8/29/2011, Vol. 19 Issue 35, p2 

    The article focuses on the different drugs made for melanoma. It mentions that the approval of Yervoy (ipilimumab) from Bristol-Myers Squibb Co. caused biotechs' confidence behind in terms of its right mechanisms of interaction. It also cites Allovectin-7 from Vical Inc., a plasmid-based...

  • Vical Presents Allovectin (R) Phase 3 Melanoma Trial.  // Biotech Business;Mar2012, Vol. 25 Issue 3, p7 

    This article reports on the success of Vical, a drug company, in designing and conducting the Phase 3 melanoma trial for its Allovectrin drug. It explains that the trial is being done through the Special Protocol Assessment process with the U.S. Food and Drug Administration (FDA). The Phase 3...

  • Vical Inc.  // San Diego Business Journal;5/27/96, Vol. 17 Issue 22, p28 

    Features Vical Inc., a pharmaceutical product manufacturer. Value; Performance record; Board of directors; Significant stock ownership.

  • Vical Inc.  // San Diego Business Journal;06/02/97, Vol. 18 Issue 22, p32 

    Presents a proxy of Vical Incorporated. Details on company's operations; Its performance record for the year ended December 31, 1996; Details on its directors; Executive compensation; Significant stock ownership; Other information related to company.

  • Decisions Update.  // PharmaWatch: Biotechnology;August 2005, Vol. 4 Issue 8, p10 

    The article reports that U.S. Food and Drug Administration (FDA) has granted Vical Inc.'s herpes vaccine orphan drug status. Vical has reported the FDA's decision to award orphan drug status to the biopharmaceutical firm's herpes vaccine. For products designated as orphan drugs, the FDA will not...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;Dec2006, Vol. 5 Issue 12, p21 

    The article offers news briefs related to pharmaceutical industry in the U.S. Vical Inc. has announced that its avian influenza deoxyribonucleic acid (DNA) vaccine provided a 100% protection in ferrets against H5N1 virus. The Food and Drug Administration (FDA) has approved the capsule...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics